-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Baricitinib is an oral, reversible and selective Janus kinase (JAK)/JAK2 inhibitor indicated for the treatment of rheumatoid arthritis (RA)
We summarized treatment-emergent adverse events in patients receiving any dose of baricitinib (All-bari-RA) from a comprehensive database (9 Phase III/II/Ib and 1 long-term extension)
The included studies included 3770 patients who received baricitinib
In conclusion, in this meta-analysis including long-term data on baricitinib in 3770 patients with active RA (median 4.
Original source:
Peter C Taylor, et al.
leave a message here